The drug still has to be approved, rememmber. We are just talking about positive data here.
Listen, I sincerely hope you're right, and we all know this current PPS is absurd, all I'm saying is I do not believe this will go to $5.00 on positive data, you do. Let's see who is right March/April time. I hope it's you.
I disagreed with a poster who said that $2.00 would be 'fair value' that's not to say I think it will be higher than that. Rememeber, everything always goes wrong here.
To answer your question, where this goes if data is a home run much depends on the SP before release.
But if I was to make a prediction I fancy $2.00 - $2.50
How do we climb to $5.00 from these levels? Are you predicting it will go to $5.00 overnight if data is successful?
Dave - You said the other week that if and when MSTX gains markey 'veracity' with strong P3 data, it changes everything?
You truly are a master in putting a dampener on things, a real scrooge.
Are you like this in real life? I bet you don't get invited to many parties.
It's a bit of fun, just guesstimating what the future PPS might be.
Totally disgaree that that is fair value for a company that has successfully completed a Phase 3 study.
Go and see how many Biotech's are out there that are valued at around 400 mil MC that have pretty much nothing and not even in a P3. There are many of them.
I would like to see approx $2.00 on top line data, and over the next 12-18 months or so around $7.00 if all goes well with heart and stroke. I will most likely be way out though. Nobody around here has really got anything right.
I'm not as stresed as I once was about what the PPS will be if we see top line data, as if all is good the PPS should look after itself as we move well into 2016..
So it's a case of wait and see if it ends or if it continues. Would be a big shame if it's the former.
I've been looking into this myself, I believe only 3 Pharma's have received this for pediatric drugs, then sell them for around 300 mil.
Can you elaborate pls? Do you think it will be signed off before Mast submit the NDA at the end of 2016? Is Quick right what he says and is it really worth 300 mil?
At todays O/S share count that would be worth $1.84 a share here.
Yes they all seem to do that, post poor results but then dangle a carrot saying 'but we still have this' BUT with this crowd they truly are in the last chance saloon, if EPIC fails then they are done, finished, kapoot. Even the heart and stroke indications will be finished as they are liked to 188, even Culley said so.
It's simply sink or swim with the EPIC data.
Must admit, I'm happy to see this at .40...if this had continued to drop we could hav been talking .30 cents which is unthinkable..
If no-one comes up with anything, it may be something worth emailing Ioana on, IF you are that bothered about it.